Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Zymeworks Inc. - Common Stock
(NQ:
ZYME
)
26.71
-0.62 (-2.27%)
Streaming Delayed Price
Updated: 1:00 PM EST, Nov 28, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
578,116
Open
27.45
Bid (Size)
26.45 (800)
Ask (Size)
26.70 (100)
Prev. Close
27.33
Today's Range
26.41 - 27.69
52wk Range
9.030 - 28.49
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Zymeworks Announces Participation in Upcoming Investor Conferences
November 24, 2025
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Stock Sees Surge In Retail Chatter After Royalty Pivot, Cancer Trial Win Sparks Target Price Hikes
↗
November 24, 2025
Strong new Phase 3 Ziihera data boosted confidence in upcoming regulatory milestones.
Via
Stocktwits
Performance
YTD
+80.7%
+80.7%
1 Month
+37.8%
+37.8%
3 Month
+80.4%
+80.4%
6 Month
+133.7%
+133.7%
1 Year
+89.6%
+89.6%
More News
Read More
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
November 18, 2025
From
MarketNewsUpdates.com
Via
GlobeNewswire
Alphabet To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
November 18, 2025
Via
Benzinga
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
5 Analysts Have This To Say About Zymeworks
↗
October 24, 2025
Via
Benzinga
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
November 18, 2025
Via
FinancialNewsMedia
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
November 18, 2025
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
November 18, 2025
From
Zymeworks Inc.
Via
GlobeNewswire
Let's take a look at the stocks that are in motion in today's session.
↗
November 17, 2025
Via
Chartmill
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans
↗
November 17, 2025
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
November 17, 2025
Via
Benzinga
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday
↗
November 17, 2025
Via
Benzinga
The market is filled with gapping stocks in Monday's session.
↗
November 17, 2025
Via
Chartmill
Mixed Signals Point to Cautious Open for U.S. Markets as Tech Shines Amidst Economic Data Delays
November 17, 2025
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Electric Vehicles
Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer
↗
November 17, 2025
Via
Investor's Business Daily
These stocks are moving in today's pre-market session
↗
November 17, 2025
Via
Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
November 17, 2025
Via
Benzinga
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
November 17, 2025
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Inc (NASDAQ:ZYME) Shows Strong Technical and Fundamental Momentum
↗
November 11, 2025
Via
Chartmill
Zymeworks Inc (NASDAQ:ZYME) Reports Mixed Q3 2025 Results with Narrower Loss but Revenue Miss
↗
November 06, 2025
Via
Chartmill
Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results
November 06, 2025
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
October 28, 2025
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
October 23, 2025
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
October 16, 2025
From
Zymeworks Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is Zymeworks Inc. - Common Stock publicly traded?
Yes, Zymeworks Inc. - Common Stock is publicly traded.
What exchange does Zymeworks Inc. - Common Stock trade on?
Zymeworks Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Zymeworks Inc. - Common Stock?
The ticker symbol for Zymeworks Inc. - Common Stock is ZYME on the Nasdaq Stock Market
What is the current price of Zymeworks Inc. - Common Stock?
The current price of Zymeworks Inc. - Common Stock is 26.71
When was Zymeworks Inc. - Common Stock last traded?
The last trade of Zymeworks Inc. - Common Stock was at 11/28/25 01:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.